Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.
Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at sinman@mjhlifesciences.com
Case Study Shows Early Efficacy for Neratinib in HER2-Mutated Metastatic Breast Cancer
September 11th 2015Treatment with the second-generation HER2/EGFR-targeted TKI neratinib resulted in a partial response and dramatic improvement in functional status for a patient with HER2-mutated breast cancer.
Read More
FDA Grants Ixazomib Priority Review in Multiple Myeloma
September 9th 2015The FDA has granted a priority review designation to the oral proteasome inhibitor ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with relapsed and/or refractory multiple myeloma.
Read More
Panobinostat Approved in Europe for Multiple Myeloma
September 4th 2015The European Commission has approved panobinostat in combination with bortezomib and dexamethasone for adult patients with relapsed/refractory multiple myeloma following prior treatment with bortezomib and an immunomodulatory agent.
Read More
FDA Expands Aprepitant's CINV Indication
September 2nd 2015The FDA has approved aprepitant capsules in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting in patients aged 12 to 17 and for those under the age of 12 who weigh at least 30 kg who are receiving chemotherapy.
Read More
Eltrombopag Approved in Europe for Severe Aplastic Anemia
September 2nd 2015The European Commission has approved eltrombopag as a treatment for adult patients with severe aplastic anemia who are refractory to immunosuppressive therapy or are heavily pretreated and not suitable for hematopoietic stem cell transplant.
Read More
FDA Grants Intravesical Immunotherapy Priority Review for Bladder Cancer
August 28th 2015The FDA has assigned a priority review designation to the intravesical immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-Guerin therapy.
Read More
Second Study Proves Daratumumab's Efficacy in Multiple Myeloma
August 27th 2015Findings from a second phase II clinical trial have demonstrated impressive signs of clinical activity with the anti-CD38 monoclonal antibody daratumumab as a monotherapy for patients with heavily pretreated multiple myelom.
Read More
FDA Expands Brentuximab Vedotin's Hodgkin Lymphoma Label
August 18th 2015The FDA has approved the antibody-drug conjugate brentuximab vedotin as a consolidation therapy following autologous stem cell transplantation in patients with Hodgkin lymphoma who are at risk of relapse or progression.
Read More
FDA Delays Decision on Frontline Nivolumab in Melanoma
August 12th 2015The FDA has extended the review period for frontline nivolumab in patients with advanced melanoma by 3 months, to allow ample time to review additional data submitted by the PD-1 inhibitor's developer Bristol-Myers Squibb.
Read More
Intraperitoneal Chemotherapy Uptake Sluggish in Ovarian Cancer
August 11th 2015Frontline treatment with intraperitoneal chemotherapy is commonly underutilized for a majority of patients with optimally cytoreduced stage III ovarian cancer, despite recommendations for its use and a clear demonstration of improved overall survival.
Read More
Telotristat Etiprate Cuts Carcinoid Syndrome-Related Diarrhea in Phase III Study
August 3rd 2015Treatment with telotristat etiprate significantly reduced the average number of daily bowel movements compared with placebo for patients with carcinoid syndrome that was not adequately controlled with a somatostatin analog.
Read More